Nasal polyps trial tests stretching biologic doses

NCT ID NCT07187583

Recruiting now Disease control Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether people with chronic nasal polyps who are stable on biologic drugs like dupilumab or mepolizumab can safely extend the time between doses from every 4 weeks to every 6 or 8 weeks. The goal is to see if symptom control can be maintained with fewer injections. 135 adults who have been on a steady dose for at least three months will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: biologic drugs (dupilumab or mepolizumab)
What this could lead to: If successful, this could allow patients with chronic nasal polyps to take their medication less often while still controlling symptoms, reducing treatment burden and side effects.
What could go wrong: This is a Phase 4 trial with only 135 participants, so results may not apply to everyone. Some patients might lose disease control with longer dosing intervals, requiring a return to the original schedule.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Contacts and locations

Locations

Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Copenhagen University, Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark
Dept of otorhinolaryngology, Aalborg University Hospital
NOT_YET_RECRUITING

Aalborg, 9000, Denmark
Dept of otorhinolaryngology, Gødstrup Regional Hospital
NOT_YET_RECRUITING

Herning, 7400, Denmark
Dept of otorhinolaryngology, Lillebaelt Hospital
NOT_YET_RECRUITING

Vejle, 7100, Denmark
Dept of otorhinolaryngology, Nordsjaellands Hospital
RECRUITING

Hillerød, 3400, Denmark
Dept of otorhinolaryngology, Odense University Hospital
NOT_YET_RECRUITING

Odense, 5000, Denmark
Dept of otorhinolaryngology, Sjællands Universitetshospital
RECRUITING

Køge, 4600, Denmark
Dept of otorhinolaryngology, head and neck surgery, Aarhus University Hospital
NOT_YET_RECRUITING

Aarhus, 8200, Denmark
Esbjerg Og Grindsted Sygehus
NOT_YET_RECRUITING

Esbjerg, 6700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.